Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial

The EXAMINE trial tested the efficacy and safety of alogliptin, an inhibitor of dipeptidyl peptidase 4, compared with placebo in 5380 patients with type 2 diabetes and a recent acute coronary syndrome. Because...

Source: BMC Medicine - June 4, 2020 Category: Internal Medicine Authors: Jo ão Pedro Ferreira, Cyrus Mehta, Abhinav Sharma, Steven E. Nissen, Patrick Rossignol and Faiez Zannad Tags: Research article Source Type: research